Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

Weight-Loss Surgery Lowers Risk of Developing Complications of Liver Disease in Patients With Cirrhosis and Obesity Jan. 27, 2025 — A study shows that patients with obesity and fatty liver ...

As cirrhosis represents a more advanced stage of liver disease with limited treatment options, Rezdiffra could become a go-to therapy for this patient population. Furthermore, positive results in ...

Seres Therapeutics Inc., a biotechnology company with a market capitalization of $116 million, reported a larger-than-expected net loss for the fourth quarter of 2024, with earnings per share (EPS) ...

ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD ...

Hosted by Terry Gross, the show features intimate conversations with today's biggest luminaries. Subscribe to Fresh Air Plus! You'll enjoy bonus episodes and sponsor-free listening - all while you ...

If you already have a liver condition such as cirrhosis, tell your doctor if you have any new or worsening symptoms. Symptoms of liver cancer are often quite vague and vary depending on where the ...

Objective: To identify and evaluate the quality of evidence supporting prophylactic use of treatments for stress ulcers and upper gastrointestinal bleeding. Stress ulcers, erosions of the stomach ...

Analysts suggest that success in this area could open up a new U.S. Total Addressable Market (TAM) of over $7 billion. As cirrhosis represents a more advanced stage of liver disease with limited ...

AATD is a condition affecting fewer than 200,000 people in the United States, characterized by pulmonary emphysema and hepatic cirrhosis, which can lead to significant morbidity. Korro’s Chief Medical ...